PureTech Health announced the nomination of a new therapeutic candidate, LYT-310, which is an oral cannabidiol CBD prodrug and the second therapeutic candidate developed from PureTech’s Glyph platform to be advanced toward the clinic. Clinical studies of LYT-310 are expected to begin in Q4 of 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRTC:
